hello world!
Published: March 13, 2018

Levetiracetam Associated With Less Monotherapy Failure in Infantile Seizures

babysickg829286758 1382859 | New Jersey Pediatric Neuroscience Institute

“Levetiracetam (Keppra) offers greater efficacy than phenobarbital in preventing monotherapy failure in infants with nonsyndromic epilepsy, according to the findings of a multicenter prospective observational study published in JAMA Pediatrics.”1

Basically, what that means, is that Keppra is more effective in preventing seizures in young children with epilepsy.

How do we know? Investigators evaluated a total of 155 infants with nonsyndromic epilepsy who were treated with levetiracetam (n=117) or phenobarbital (n=38) as initial monotherapy within 1 year of the first afebrile seizure. Infants were treated in 17 US pediatric epilepsy centers during a 3-year period (2012 to 2015). A 6-month freedom from monotherapy failure, as defined by seizure freedom within 3 months of treatment initiation and no additional prescribed antiepileptic medication, comprised the binary outcome.1

We have a new PEDIATRIC NEUROLOGIST, who specializes in treating children with epilepsy.  Please call us and ask to see Dr. Leyda Sanchez-Ortiz.

1.       https://www.neurologyadvisor.com/epilepsy/infantile-seizures-levetiracetam-monotherapy-efficacy/article/748039/

Schedule an Appointment Today

Caring for your child's well-being is our number one priority. 
Schedule an appointment with a world-class pediatric neurology and neurosurgery team at NJPNI now.
Schedule an Appointment Today

NOTICE: This website is for informational purposes only and is not intended as medical advice or as a substitute for a patient/physician relationship.

NJPNI is committed to creating a culturally diverse, inclusive and collaborative community for patients and their families, employees and associates where each person is celebrated and has a sense of equal belonging. See our DEI Statement Page for more information.

NJPNI does not exclude, deny benefits to, or otherwise discriminate against any person on the grounds of race, color, or national origin, or on the basis of disability or age in admission to, participation in, or receipt of the services and benefits of any of its programs and activities or in employment therein. This statement is in accordance with the provisions of Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973, the Age Discrimination Act of 1975, and Regulations of the U.S. Department of Health and Human Services issued pursuant to the Acts, Title 45 Code of Federal Regulations part 80, 84, and 91.

Copyright © 2024 New Jersey Pediatric Neuroscience Institute

Privacy Policy | Notice of Non-Discrimination

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram